Asia Pacific Building Construction Industry Report 2020: Value and Volume, Market Segments, Opportunities in Top 100 Cities, and Risk Assessment - COVID-19 Update Q2 2020 - ResearchAndMarkets.com
The building construction industry in Asia Pacific is expected to record a CAGR of 10.1% to reach USD 3126.7 billion by 2024. The residential construction industry in value terms increased at a CAGR of 7.6% during 2015-2019. The commercial building construction market in value terms is expected to record a CAGR of 11.9% over the forecast period.
Building construction industry in Asia Pacific is expected to record a period of negative / low growth over the next 8 quarters, driven by economic downturn triggered due to Covid-19 outbreak.
While impact across building construction sectors varies, residential, commercial, and industrial segments are expected to be worst affected. Business and consumer sentiment is expected to be on a slow track to recover due to pandemic, resulting in prolonged distress building construction sectors.
In residential sector, affordable housing is expected to stay least affected, supported by a mix of public and private spending. Mid-tier and luxury residential construction segments are expected to be severely impacted. Growth across commercial building construction in Asia Pacific, especially office, retail, and entertainment is expected to record negative growth.
This report provides data and trend analyses on asian building construction industry, with over 80 KPIs. This is a data-centric report and it provides trend analyses with over 1,300+ charts and 1,200+ tables. It details market size & forecast, emerging trends, market opportunities, and investment risks in over 30 segments in residential, commercial, industrial, and institutional construction sectors.
It provides a comprehensive understanding of construction industry sectors in both value and volume (both by activity and units) terms. The report focuses on combining industry dynamics with macro-economic scenario and changing consumer behavior to offer a 360-degree view of the opportunities and risks.
In addition to country level analysis, this report offers a detailed market opportunity assessment across top 100 cities, helping clients assess key regions to target within the city.
Report Scope
Market Data and Insights: This report provides market size and forecast across 40+ construction segments for a period of 10 years from 2015-2024 in Asia.
KPIs covered include the following:
Market size by value
Market size by volume of construction
Number of units
Residential Building Construction Coverage: 10-year market size & forecast in value and volume (area and units) terms by
Infrastructure Construction Sectors: 10- year market size & forecast in value terms by
Marine and inland water infrastructure
Utility system construction (oil and gas infrastructure, communication infrastructure, power infrastructure, water and sewer infrastructure)
Transportation infrastructure (highway, street and bridge construction, railway construction, airport construction, and tunnel construction)
Construction stage (new construction, re-development, maintenance)
Cities Covered
China
India
Australia
Indonesia
Thailand
Malaysia
Philippines
Bangladesh
Vietnam
Sri Lanka
Reason to Buy
In-depth Understanding of Building Construction Market Dynamics: Understand market opportunity, industry dynamics, key trends and drivers across 30+ market segments and sub-segments of Asia building construction industry.
Volume and Value Data: Get a detailed understanding of the market both from value and volume (both by activity and units) perspective for the historical as well as the forecast period
Develop Market Specific Strategies: Identify growth segments and target specific opportunities to formulate your strategy; assess market specific key trends, drivers and risks in the construction industry.
City Level Insights: Get city level trend analyses to identify unique opportunities across top 150 cities and also by tier-1, tier-2, and tier-3 cities.
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug...
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the first quarter of 2024. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with...
The First Bancshares, Inc. ("FBMS" or "the Company") , holding company for The First Bank, (www.thefirstbank.com) reported today financial results for the quarter ended March 31, 2024.
Highlights for the Quarter:
Net income available to common...
Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in thedevelopment oftherapeutics for age-related...
Alamos Gold Inc. ("Alamos" or the "Company") today reported its financial results for the quarter ended March 31, 2024. "We delivered another strong start to the year across a number of fronts, following a record performance in 2023. Costs...